Sunday 27th August 2023

Pre-conference courses

TIME	ROOM U6.1a	ROOM U6.1b	ROOM U6.1e	ROOM U6.1f
9:00-10:30		**Estimands and analyses of longitudinal continuous outcomes in clinical trials** **Teachers:** Marcel Wolbers, Alessandro Noci	**Beyond classic epidemiological designs** **Teachers:** Marie Reilly, Paola Rebora, Francesca Graziano	**Pseudo observations in survival analysis** **Teachers:** Per Kragh Andersen, Henrik Ravn
10:30-11:00	COFFEE BREAK			
11:00-12:30		**Estimands and analyses of longitudinal continuous outcomes in clinical trials** **Teachers:** Marcel Wolbers, Alessandro Noci	**Beyond classic epidemiological designs** **Teachers:** Marie Reilly, Paola Rebora, Francesca Graziano	**Pseudo observations in survival analysis** **Teachers:** Per Kragh Andersen, Henrik Ravn
12:30-13:30	LUNCH BREAK			
13:30 - 15:00	**Evaluation of prediction models: from AUC to calibration and decision curve analysis** **Teachers:** Ewout Steyerberg, Ben van Calster, Ed Bonneville	**Analysis of genomic data: R Bioconductor** **Teacher:** Davide Risso	**Beyond classic epidemiological designs** **Teachers:** Marie Reilly, Paola Rebora, Francesca Graziano	**Pseudo observations in survival analysis** **Teachers:** Per Kragh Andersen, Henrik Ravn
15:00-15:30	COFFEE BREAK			
15:30 - 17:00	**Evaluation of prediction models: from AUC to calibration and decision curve analysis** **Teachers:** Ewout Steyerberg, Ben van Calster, Ed Bonneville	**Analysis of genomic data: R Bioconductor** **Teacher:** Davide Risso	**Beyond classic epidemiological designs** **Teachers:** Marie Reilly, Paola Rebora, Francesca Graziano	**Pseudo observations in survival analysis** **Teachers:** Per Kragh Andersen, Henrik Ravn
19:00-21:00	**Students/ECB gathering at Fuorimano OTBP**			

Monday 28th August 2023

TIME	ROOM U6.6	ROOM U6.7	ROOM U6.8	ROOM U6.9	ROOM U6.10	ROOM U6.11	AULA MAGNA/GREAT HALL INVITED SESSIONS
09:00-10:30	**GREAT HALL** **CONFERENCE OPENING:** **PLE1: Plenary Lecture 1: Keynote speaker: Lisa McShane** ***"Statistical adventures in pursuit of precision medicine: secret signatures, sliding subgroups & more"***						
10:30-11:00	**COFFEE BREAK**						
11:00-12:30	MO1 Clinical Trials 1	MO2 Survival analysis 1	MO3 Prediction models 1	MO4 Biomarkers	M05 High dimensional data 1	MO6 Epidemiology 1	MIN 1 Advances on causal inference in longitudinal studies
12:30-13:30	**LUNCH BREAK**						
13:30-15:00	MO7 Clinical Trials 2	MO8 Survival analysis 2	MO9 Latent variable modelling	MO10 Causal inference 1	MO11 Machine learning 1	MO12 Real world data	MIN 2 Innovative designs for dose optimization studies
15:00-15:30	**COFFEE BREAK**						
15:30-17:00	MO13 Clinical Trials 3	MO14 Survival analysis 3	MO15 Precision Medicine 1	MO16 Longitudinal analysis 1	MO17 High dimensional data 2	MO18 Meta-Analysis	MIN 3 Vaccination programmes: post-implementation assessment of protection, benefits and risks
19:00-21:00	**WELCOME RECEPTION**						

Tuesday 29th August 2023							
TIME	**ROOM U6.6**	**ROOM U6.7**	**ROOM U6.8**	**ROOM U6.9**	**ROOM U6.10**	**ROOM U6.11**	**AULA MAGNA/GREAT HALL** INVITED SESSIONS
9:00-10:30	TO1 Clinical Trials 4	TO2 Survival analysis 4	TO3 Students Awardees	TO4 Causal inference 2	TO5 Machine learning 2		TIN 1 Evaluation of predictive algorithms and models: uncertainty and impact on medical care
10:30-11:00	**COFFEE BREAK**						
11:00-12:30	TO6 Clinical Trials 5	TO7 Survival analysis 5	TO8 Prediction models 2	TO9 Longitudinal analysis 2	TO10 Clinical Trials 6	TO11 ItR-IBS & Italian Statistical Society	TIN 2 High-dimensional inference in biostatistics
12:30-13:30	**LUNCH BREAK**						
13:30-18:00	**EXCURSIONS**						

Wednesday 30th August 2023							
TIME	**ROOM U6.6**	**ROOM U6.7**	**ROOM U6.8**	**ROOM U6.9**	**ROOM U6.10**	**ROOM U6.11**	**AULA MAGNA/GREAT HALL INVITED SESSIONS**
09:00-10:30	WO1 Clinical Trials 7	WO2 Survival analysis 6	WO3 Longitudinal analysis 3	WO4 Causal inference 3	WO5 Missing data	WO6 Epidemiology 2	WIN1 Recurrent events and their use in medical studies
10:30-11:00	**COFFEE BREAK**						
11:00 - 13:30	**GREAT HALL** **PLE2: Plenary Lecture 2: President invited speaker** **Vanessa Didelez** ***"On causal inference, estimands and trials in epidemiology and biostatistics"*** **12:30 ROOM U6.6 - ISCB Annual General Meeting (AGM)**						
13:30-15:00	WO7 Clinical Trials 8	WO8 13:20-15:00 Dedicated to Prof. Marubini Survival analysis 7	WO9 Prediction models 3	WO10 Causal inference 4	WO11 Machine learning 3	WO12 Syntetic data 1	WIN 2 Quantification of safety signals in clinical trials: estimand, estimation, and how would good look like in ten years?
15:00-15:30	**COFFEE BREAK**						
15:30-17:00	WO13 Clinical Trials 9	WO14 Miscellanea	WO15 Precision Medicine 2	WO16 Longitudinal analysis 4	WO17 High dimensional data 3		WIN3 Marginal versus conditional effects in clinical trials
19:00-21:00	**CONFERENCE DINNER: VILLA REALE (MZ) - Meeting point at Building University of Milano-Bicocca at 18:30**						

Thursday 31th August 2023 Mini-symposia 1 and 2 and Early Career Biostatistician (ECB) Day			
	ROOM U6.6	**ROOM U6.8**	**ROOM U6.9**
9:00-10:30	**TMS1** **Mini-symposium 1: Ten years STRATOS initiative – brief summary of progress and plans for the future**	**TMS2** **Mini-symposium 2: Novel approaches to complex data and predictive modeling in healthcare research**	**ECB** **Early Career Biostatisticians' (ECB) Day**
10:30-11:00	**COFFEE BREAK**		
11:00-12:30	**TMS1** **Mini-symposium 1: Ten years STRATOS initiative – brief summary of progress and plans for the future**	**TMS2** **Mini-symposium 2: Novel approaches to complex data and predictive modeling in healthcare research**	**ECB** **Early Career Biostatisticians' (ECB) Day**
12:30-13:30	**LUNCH BREAK**	**ROOM U6.10 - 12:30 General Meeting of the Italian Region of IBS**	
13:30-15:00	**TMS1** **Mini-symposium 1: Ten years STRATOS initiative – brief summary of progress and plans for the future**		
15:00-15:30	**COFFEE BREAK**		
15:30-17:00	**TMS1** **Mini-symposium 1: Ten years STRATOS initiative – brief summary of progress and plans for the future**		

Monday 28th August 2023

TIME		ROOM U6.6	ROOM U6.7	ROOM U6.8	ROOM U6.9	ROOM U6.10	ROOM U6.11	AULA MAGNA/GREAT HALL INVITED SESSION
9:00 - 10:30		**GREAT HALL** **PLE1: Plenary Lecture 1: Keynote speaker: Lisa McShane** **"Statistical adventures in pursuit of precision medicine: secret signatures, sliding subgroups & more"**						
10:30-11:00		COFFEE BREAK						
		MO1 **CLINICAL TRIALS 1**	MO2 **SURVIVAL ANALYSIS 1**	MO3 **PREDICTION MODEL 1**	MO4 **BIOMARKERS**	MO5 **HIGH DIMENSIONAL DATA 1**	MO6 **EPIDEMIOLOGY 1**	**MIN1 - Advances on causal inference in longitudinal studies**
11:00 - 12:30	11:00	MO1.1 ADAPTIVE SEAMLESS DESIGNS IN THE TWO-TRIAL PARADIGM: ADVANTAGES AND LIMITATIONS; Stella Jinran Zhan	MO2.1 PERILS OF RCT SURVIVAL EXTRAPOLATION WITH EFFECT WANING: WHY MARGINAL AND CONDITIONAL ESTIMATES DIFFER; Angus Jennings	MO3.1 TUNING THE REGULARIZATION PARAMETER IN PENALIZED REGRESSION: AN APPROACH BASED ON FALSE SELECTION RATE; Matteo Rota	MO4.1 VALIDATION OF A SKEWED SURROGATE ENDPOINT FOR A TIME-TO-EVENT OUTCOME: THE USE OF A ZAGA DISTRIBUTION; Giulia Risca	MO5.1 CONDITIONAL VARIABLE SCREENING FOR ULTRA-HIGH DIMENSIONAL LONGITUDINAL DATA WITH TIME INTERACTIONS; Andrea Bratsberg	MO6.1 LINKED SHRINKAGE TO IMPROVE THE ESTIMATION OF INTERACTION EFFECTS IN A REGRESSION MODEL; Mark Van de Wiel	**Organizer:** Cécile Proust-Lima
	11:19	MO1.2 POWER CALCULATIONS FOR MULTI-ARM MULTI-STAGE TRIALS WITH MULTI-COMPONENT DISEASE RATING SCALES OUTCOMES [+]; James Carpenter	MO2.2 CAN WE TRUST THE HAZARD RATIO? -CAUSAL CONSEQUENCES OF OBSERVED PROPORTIONAL HAZARDS; Morten Valberg	MO3.2 PENALISED REGRESSION METHODS WITH MODIFIED TUNING PRODUCE BETTER PREDICTION MODELS; Menelaos Pavlou	MO4.2 METRICS OF SPATIAL INTERACTION BETWEEN IMMUNE AND CANCER CELLS IN TUMOR MICROENVIRONMENT AS CANCER BIOMARKERS; Inna Chervoneva	MO5.2 INCORPORATING EXTERNAL INFORMATION INTO BAYESIAN ADDITIVE REGRESSION TREES USING EMPIRICAL BAYES; Jeroen Goedhart	MO6.2 NOVEL INSIGHTS FOR QUANTIFYING SELECTION BIAS USING INTERACTIONS ON THE LOG-ADDITIVE SCALE; Apostolos Gkatzionis	MIN1.1 Longitudinal outcome-adaptive and marginal fused LASSO for confounder selection and model pooling with time-varying treatments; Mireille Schnitzer
	11:37	MO1.3 FAST SIMULATION OF BAYESIAN ADAPTIVE DESIGNS USING THE LAPLACE APPROXIMATION; Stephane Heritier	MO2.3 A NON-PARAMETRIC PROPORTIONAL RISK MODEL TO ASSESS A TREATMENT EFFECT IN AN APPLICATION TO SURVIVAL DATA; Lucia Ameis	MO3.3 AN INTRODUCTION TO PROJECTION PREDICTIVE VARIABLE SELECTION; Frank Weber	**MO4.3 - ONLINE** BAYESIAN NETWORK META-ANALYSIS OF TIME-TO-EVENT DATA FOR EVALUATION OF PREDICTIVE BIOMARKERS USING IPD AND AD; Chinyereugo Chikere	MO5.3 A FRAMEWORK FOR INTERPRETATION AND TESTING OF SPARSE CANONICAL CORRELATIONS; Nuria Senar	MO6.3 INVESTIGATING ACCURACY OF DISEASE OUTCOME DEFINITION IN PHARMACOEPIDEMIOLOGY: BAYESIAN LATENT CLASS MODEL; Satoshi Uno	MIN1.2 Proximal Causal Inference for Separable Effects With Applications to Aging Research; Eric Tchetgen Tchetgen
	11:55	MO1.4 A BAYESIAN DECISION-THEORETIC RANDOMISATION PROCEDURE AND THE IMPACT OF DELAYED RESPONSES; S. Faye Williamson	MO2.4 A REDUCED RANK PROPORTIONAL HAZARDS MODEL FOR AGE-RELATED MULTIMORBIDITY EVENT DATA; Marije Sluiskes	MO3.4 CONFIDENCE INTERVAL ESTIMATION FOR SELECTED AND UNSELECTED PREDICTORS AFTER VARIABLE SELECTION; Nilufar Akbari	MO4.4 AGREEMENT AND ERROR OF TITRATION ASSAYS; Neal Alexander	MO5.4 TWO-DIMENSIONAL FUSED TARGETED RIDGE ESTIMATION FOR HEALTH INDICATOR PREDICTION; Wessel van Wieringen	MO6.4 INCREASE EFFICIENCY AND REDUCE BIAS WHEN ASSESSING HPV VACCINATION EFFICACY BY USING NON-TARGETED HPV STRAINS; Lola Etievant	MIN1.3 Risk prediction under hypothetical interventions; Ruth Keogh
	12:13	MO1.5 EVALUATING THE IMPACT OF OUTCOME DELAY ON THE EFFICIENCY OF TWO-ARM GROUP-SEQUENTIAL TRIALS; Aritra Mukherjee	MO2.5 MULTICASANOVA - MULTIPLE GROUP COMPARISONS FOR NON-PROPORTIONAL HAZARD SETTINGS; Ina Dormuth			MO5.5 METHODOLOGY FOR, AND INSIGHT FROM, ANALYSING DISPLACEMENT BY TREMOR IN PARKINSON'S DISEASE; Kieran Baker	MO6.5 QUANTIFYING THE EFFECT OF MOBILITY RESTRICTIONS ON HEALTH POLICIES DURING THE PANDEMIC: A FDA APPROACH; Francesca Ieva	
12:30-13:30		LUNCH BREAK						

Monday 28th August 2023

TIME		ROOM U6.6	ROOM U6.7	ROOM U6.8	ROOM U6.9	ROOM U6.10	ROOM U6.11	AULA MAGNA/GREAT HALL INVITED SESSIONS
		MO7 CLINICAL TRIALS 2	MO8 SURVIVAL ANALYSIS 2	MO9 LATENT VARIABLE MODELLING	MO10 CAUSAL INFERENCE 1	MO11 MACHINE LEARNING 1	MO12 REAL WORLD DATA	**MIN2 - Innovative designs for dose optimization studies**
13:30 - 15:00	13:30	MO7.1 ESTIMATING THE TREATMENT EFFECT IN A CLINICAL TRIAL; Erik van Zwet	**MO8.1 - ONLINE** GRADIENT BOOSTING FOR SURVIVAL ANALYSIS WITH COMPETING RISKS; Nofel Ahmed *	MO9.1 RANDOM EFFECTS MODELS OF TUMOUR GROWTH AND INTERVAL BREAST CANCER - A STUDY OF INCIDENT CASES; Letizia Orsini	MO10.1 G-FORMULA FOR CAUSAL INFERENCE VIA MULTIPLE IMPUTATION; Jonathan Bartlett	MO11.1 FUZZY SETS IN PROBABILITY TREES: A NOVEL INTERPRETABLE AI DECISION MAKING MODEL; Giulia Capitoli	MO12.1 EMULATING AN EXISTING TRIAL OF TREATMENTS FOR PROSTATE CANCER USING REAL-WORLD DATA: METHODS AND CHALLENGES; Caroline Chesang	**Organizer:** Emily Zabor
	13:49	MO7.2 ROBUST INCORPORATION OF EXTERNAL INFORMATION IN HYPOTHESIS TESTING; Silvia Calderazzo	MO8.2 IMPUTING MISSING COVARIATES FOR COMPETING RISKS ANALYSES WHEN USING THE FINE–GRAY MODEL; Edouard Bonneville	MO9.2 LATENT DYNAMIC MODELING WITH DIFFERENTIAL EQUATIONS FOR INDIVIDUAL DISEASE TRAJECTORIES; Maren Hackenberg	MO10.2 IMPLEMENTATION OF G-COMPUTATION IN PRACTICE: A NEW DIAGNOSTIC TOOL TO GUIDE OUTCOME MODEL SPECIFICATION; Daisy Shepherd	MO11.2 RANDOM SURVIVAL FORESTS FOR ANALYSING SURVIVAL DATA WITH RECURRENT EVENTS; Juliette Murris	MO12.2 AUGMENTING TREATMENT ARMS WITH DATA FROM EXPANDED ACCESS USING PROPENSITY-SCORE WEIGHTED POWER PRIORS; Joost van Rosmalen	MIN2.1 The Use of Master Protocol Designs with Dose-Optimization Studies; Alex Kaizer
	14:07	MO7.3 TESTING FOR SIMILARITY OF MULTIVARIATE MIXED OUTCOMES WITH APPLICATION TO EFFICACY-TOXICITY RESPONSES; Niklas Hagemann	MO8.3 SIMILARITY OF COMPETING RISKS MODELS WITH CONSTANT INTENSITIES IN AN APPLICATION TO HEALTHCARE PATHWAYS; Kathrin Möllenhoff	MO9.3 UNIFYING PROBABILITY AND NON-PROBABILITY SAMPLES WITH MISCLASSIFIED COVARIATE FOR IMPROVED INFERENCE; Hua Shen	MO10.3 INVESTIGATING POSITIVITY VIOLATIONS IN MARGINAL STRUCTURAL SURVIVAL MODELS: A STUDY ON ESTIMATOR PERFORMANCE; Marta Spreafico	MO11.3 * EVALUATING THE SAMPLE SIZE REQUIREMENTS OF TREE-BASED MACHINE LEARNING TECHNIQUES FOR CLINICAL RISK PREDICTION; Oya Kalaycioglu	MO12.3 SEQUENCE ANALYSIS TECHNIQUES TO EVALUATE DRUGS-BASED DIAGNOSTIC THERAPEUTIC PATHS IN HEART FAILURE PATIENTS; Nicole Fontana	MIN2.2 DEMO: Bayesian Adaptive Dose Exploration–Monitoring–Optimization Design based on Short, Intermediate, and Long-term Outcomes; Ruitao Lin
	14:25	MO7.4 COMPARING STATISTICAL MODELS TO ESTIMATE CAUSAL TREATMENT EFFECTS IN AGGREGATED N-OF-1 TRIALS; Thomas Gärtner	MO8.4 DEVELOPING & VALIDATING A COMPETING RISK JOINT MODEL TO CHARACTERISE THE PROGNOSIS OF PROSTATE CANCER PATIENTS; Harry Parr	MO9.4 CORRECTLY ACCOUNTING FOR MISCLASSIFICATION WHEN LINKING LATENT GROUPS WITH EXTERNAL VARIABLES; Cécile Proust-Lima	MO10.4 ESTIMATING OPTIMAL DYNAMIC TREATMENT REGIME FOR SURVIVAL TIME OUTCOME USING G-ESTIMATION; Shaun Seaman	MO11.4 IMPACT OF TEMPORAL BREAST DENSITY CHANGES ON THE PREDICTION OF BREAST CANCER IN WOMEN FROM SCREENING PROGRAMS; Manel Rakez	MO12.4 DEVELOPING AN ALGORITHM TO IDENTIFY BREAST CANCER RECURRENCES USING ROUTINELY COLLECTED DATA IN ENGLAND; Jake Probert	MIN2.3 Controlled amplification in oncology dose-finding trials; Hakim-Moulay Dehbi
	14:43	MO7.5 MULTIMODAL OUTCOMES IN N-OF-1 TRIALS: COMBINING DEEP LEARNING AND STATISTICAL INFERENCE; Juliana Schneider	MO8.5 A NOVEL CASE-COHORT ANALYTICAL FRAMEWORK FOR SEMI-COMPETING RISKS WITHIN THE FREQUENTIST PARADIGM; Amy Zhou	MO9.5 ESTIMATION OF THE CAUSES OF FEVER USING PARTIAL LATENT CLASS ANALYSIS; Suzanne Keddie	MO10.5 HANDLING SYMPTOMATIC TREATMENT IN ALZHEIMER'S DISEASE TRIALS – ESTIMATORS FOR A HYPOTHETICAL STRATEGY; Florian Lasch	MO11.5 USING CHATGPT FOR CLASSIFICATION OF PEDIATRIC INJURIES FROM EMERGENCY DEPARTMENT RECORDS; Giulia Lorenzoni	MO12.5 OUTLIER DETECTION IN CLINICAL PERFORMANCE MONITORING AND COMPARISON OF COMMONLY USED METHODS; Anqi Sui	
15:00-15:30		COFFEE BREAK						
		MO13 CLINICAL TRIALS 3	MO14 SURVIVAL ANALYSIS 3	MO15 PRECISION MEDICINE 1	MO16 LONGITUDINAL ANALYSIS 1	MO17 HIGH DIMENSIONAL DATA 2	MO18 META-ANALYSIS	**MIN3 - Vaccination programmes: post - implementation assessment of protection, benefits and risks**
15:30 - 17:00	15:30	MO13.1 ELASTIC PRIORS TO DYNAMICALLY BORROW INFORMATION FROM HISTORICAL DATA IN CLINICAL TRIALS; Ying Yuan	MO14.1 CLINICAL TRIAL DESIGN BASED ON A MULTISTATE MODEL THAT JOINTLY MODELS PROGRESSION-FREE AND OVERALL SURVIVAL; Kaspar Rufibach	MO15.1 A BAYESIAN NONPARAMETRIC APPROACH TO PERSONALIZED TREATMENT SELECTION; Matteo Pedone	MO16.1 COMBINED SHRINKAGE OF FIXED AND RANDOM EFFECTS IN LINEAR MIXED MODELS USING EMPIRICAL BAYES; Matteo Amestoy	MO17.1 A BARTLETT-TYPE CORRECTION FOR LIKELIHOOD RATIO TESTS FOR TESTING EQUALITY OF GAUSSIAN GRAPHICAL MODELS; Erika Banzato	MO18.1 BIAS CORRECTIONS FOR STUDY WEIGHTS IN META-ANALYSES WITH BINARY OUTCOMES; Stephen Walter	**Organizer:** Marie Reilly
	15:49	MO13.2 DYNAMIC BORROWING OF HETEROGENEOUS HISTORICAL CONTROLS: HOW TO AVOID CHERRY PICKING?; Emma Gerard	MO14.2 MODELLING THE HAZARD OF TRANSITION INTO THE ABSORBING STATE IN THE ILLNESS-DEATH MODEL; Elena Tassistro	MO15.2 PRECISION MEDICINE IN TYPE 2 DIABETES: BAYESIAN NON-PARAMETRIC MODELLING OF GLUCOSE-LOWERING THERAPY EFFICACY; Pedro Cardoso	MO16.2 A BAYESIAN FUNCTIONAL PRINCIPAL COMPONENT ANALYSIS FRAMEWORK FOR LONGITUDINAL GENOME-WIDE ASSOCIATION STUDIES; Daniel Temko	MO17.2 PEARSON'S CHI-SQUARED MEETS DISTANCE AND KERNEL TESTS: AN APPLICATION TO COMPLEX DISEASE GENETICS; Fernando Castro-Prado	MO18.2 BAYESIAN NONPARAMETRIC APPROACHES AND THE BIAS-CORRECTED META-ANALYSIS MODEL FOR COMBINING DISPARATE STUDIES; Pablo Verde	MIN3.1 Statistical methods for the epidemiological evaluation of vaccine safety; Heather Whitaker
	16:07	MO13.3 INCORPORATING HISTORICAL DATA IN THE DESIGN AND ANALYSIS OF SMALL POPULATION CLINICAL TRIALS; Haiyan Zheng	MO14.3 BAYESIAN BLOCKWISE INFERENCE FOR JOINT MODELS OF LONGITUDINAL AND MULTISTATE PROCESSES; Sida Chen	MO15.3 ESTIMATING OPTIMAL RULES FOR PERSONALIZED TREATMENT DECISIONS THROUGH FUNCTIONAL SURVIVAL ANALYSIS; Caterina Gregorio	**MO16.3 - ONLINE** A BAYESIAN MODEL TO STUDY THE GENETIC RISKS DRIVING ALZHEIMER'S DISEASE PROGRESSION PATTERNS; Nemo Fournier	MO17.3 EXPLORING BETWEEN-SUBJECT CONSISTENCY IN FMRI SIGNALS THROUGH PARTIAL CONJUNCTION NULL HYPOTHESES; Anna Vesely	MO18.3 PROSPECTIVE AND RETROSPECTIVE SEQUENTIAL META-ANALYSIS USING TRIAL SEQUENTIAL ANALYSIS; Anne Lyngholm Soerensen	MIN3.2 Monitoring and evaluating Covid-19 vaccination programmes: real world challeges; Susan Hahne
	16:25	MO13.5 EXTRAPOLATION IN PEDIATRICS USING BAYESIAN DYNAMIC BORROWING, TIPPING POINT ANALYSIS AND EXPERT ELICITATION; Elvira Erhardt	MO14.4 MODEL SELECTION STRATEGIES FOR MULTI-STATE MODELING INCORPORATING MOLECULAR DATA; Kaya Miah	MO15.4 CAUSAL EFFECTS OF SALVAGE THERAPY USING JOINT MODELS FOR LONGITUDINAL AND TIME-TO-EVENT DATA; Dimitris Rizopoulos	MO16.4 DISTRIBUTIONAL MODELS FOR THE QUANTIFICATION OF WITHIN-INDIVIDUAL LUNG FUNCTION VARIABILITY IN CYSTIC FIBROSIS; Marco Palma	MO17.4 TOWARDS A POWER ANALYSIS AND SAMPLE SIZE ESTIMATION FOR PLS-BASED METHODS; Angela Andreella	MO18.4 PSEUDO-VALUES APPROACH FOR QUANTILE ANALYSIS IN INDIVIDUAL PATIENT DATA META-ANALYSIS; Alessandra Meddis	MIN3.3 Statistical methods to assess immunological surrogate endpoints for vaccines; Andrea Callegaro
	16:43				**MO16.5 - ONLINE** A HIERARCHICAL MODELLING APPROACH FOR PRINCIPAL COMPONENTS ANALYSIS ON MULTIPLE LONGITUDINAL VARIABLES; Tui Nolan	MO17.5 SELECTIVE INFERENCE IN FACTORIAL DESIGNS WITH HIGH-DIMENSIONAL RESPONSE; Livio Finos		

*** WINNERS OF ISCB CONFERENCE AWARD FOR SCIENTISTS**

Tuesday 29th August 2023

TIME		ROOM U6.6	ROOM U6.7	ROOM U6.8	ROOM U6.9	ROOM U6.10	ROOM U6.11	AULA MAGNA/GREAT HALL INVITED SESSIONS
		TO1 CLINICAL TRIALS 4	**TO2 SURVIVAL ANALYSIS 4**	**TO3 STUDENTS AWARD**	**TO4 CAUSAL INFERENCE 2**	**TO5 MACHINE LEARNING 2**		**TIN1-Evaluation of predictive algorithms and models: uncertainty and impact on medical care**
9:00 - 10:30	09:00	TO1.1 HOW (NOT) TO CONDUCT A SIMULATION STUDY FOR A TRIAL DESIGN: A CASE OF DOSE-FINDING CLINICAL TRIALS; Pavel Mozgunov	TO2.1 SIGN-FLIP TEST FOR COEFFICIENTS IN THE COX REGRESSION MODEL; Riccardo De Santis	TO3.1 SENSITIVITY ANALYSIS FOR MISSINGNESS ASSUMPTIONS IN CAUSAL INFERENCE: ACCOMMODATING THE SUBSTANTIVE ANALYSIS; Jiaxin Zhang	TO4.1 IS INVERSE PROBABILITY OF CENSORING WEIGHTING A SAFE ALTERNATIVE TO PER-PROTOCOL ANALYSIS?; Jingyi Xuan	TO5.1 ENSEMBLE ALGORITHM BASED ON SHAPLEY VALUES BEYOND BINARY CLASSIFICATION: SIMULATIONS AND CLINICAL APPLICATION; Davide Bernasconi		**Organizer:** Ewout Steyerberg
	09:19	TO1.2 USING CTDNA AS A NOVEL BIOMARKER OF EFFICACY FOR DOSE-FINDING TRIALS IN ONCOLOGY; Xijin Chen	TO2.2 PENALIZED LIKELIHOOD ESTIMATION OF COX MODELS WITH DOUBLY TRUNCATED AND INTERVAL CENSORED SURVIVAL TIMES; Annabel Webb	TO3.2 A LOCATION-SCALE JOINT MODEL WITH A TIME-DEPENDENT SUBJECT-SPECIFIC VARIANCE OF THE MARKER AND COMPETING EVENT; Léonie Courcoul	TO4.2 COMBINING SEQUENTIAL STRATIFICATION AND IPTW WEIGHTS TO ESTIMATE THE SURVIVAL BENEFIT OF LIVER TRANSPLANTATION; Ilaria Prosepe	TO5.2 COMPARISON OF CLASSIFICATION METHODS FOR MULTIPLEX DIGITAL PCR DATA; Yao Chen		TIN1.1 Sources of uncertainty in clinical prediction models; Ben van Calster
	09:37	TO1.3 ESTIMATING THE SIMILARITY BETWEEN ADULT AND PEDIATRIC DOSE-TOXICITY CURVES TO INFORM PEDIATRIC DOSE-FINDING; Dario Zocholl	TO2.3 IMPACT OF NON-INFORMATIVE CENSORING ON PROPENSITY SCORE BASED ESTIMATES OF MARGINAL HAZARD RATIOS; Guilherme Wang de Faria Barros	TO3.3 A BAYESIAN JOINT MODELLING FOR MISCLASSIFIED INTERVAL-CENSORING AND COMPETING RISKS; Zhenwei Yang	TO4.3 REDUCING TIME-LAG BIAS WHEN COMPARING TREATED PATIENTS TO CONTROLS WITH A DIFFERENT START OF FOLLOW-UP; Rik van Eekelen	TO5.3 COMPARATIVE ANALYSIS OF SUPERVISED INTEGRATIVE METHODS FOR MULTI-OMICS DATA; Camilo Broc		TIN1.2 Reporting and Methodological quality of machine learning prediction model studies: an overview of results; Paula Dhiman
	09:55	TO1.4 INCORPORATING PATIENT-REPORTED OUTCOMES IN DOSE-FINDING CLINICAL TRIALS WITH CONTINUOUS PATIENT ENROLLMENT; Anais Andrillon	TO2.4 IMPACT OF OMITTED COVARIATES ON TREATMENT ESTIMATES IN PROPENSITY SCORE MATCHED STUDIES; Alexandra Strobel	TO3.4 A JOINT MODEL FOR (UN)BOUNDED LONGITUDINAL MARKERS, COMPETING RISKS, AND RECURRENT EVENTS USING REGISTRY DATA; Pedro Miranda Afonso	TO4.4 BASING DISCRETE EVENT SIMULATORS FOR ORGAN ALLOCATION ON COUNTERFACTUAL MORTALITY RISKS; Hans de Ferrante	TO5.4 OPTIMAL TRANSPORT FOR AUTOMATIC ALIGNMENT OF NON-TARGETED METABOLOMIC DATA; Marie Breeur		
	10:13	TO1.5 DESIGNING PATIENT-CENTRED DOSE-FINDING TRIALS WITH PATIENT-REPORTED OUTCOMES: OPPORTUNITIES AND CHALLENGES; Emily Alger	TO2.5 COMPARING OVERALL BENEFIT/RISK OF TREATMENTS BY WEIGHTED COX MODEL ON ORDERING SCORES FOR RELEVANT EVENTS; Ákos Ferenc Pap	TO3.5 PARAMETRIC ESTIMATION OF THE MEAN NUMBER OF EVENTS IN THE PRESENCE OF COMPETING RISKS; Joshua Philipp Entrop	TO4.5 CONTINUOUS-TIME MEDIATION ANALYSIS FOR REPEATED MEDIATORS AND OUTCOMES; Kateline Le Bourdonnec	**TO5.5** - **ONLINE** ARTIFICIAL INTELLIGENCE FOR THE PREDICTION OF WEANING READINESS OUTCOME IN MECHANICALLY VENTILATED PATIENTS; Corrado Lanera		TIN1.3 Measuring clinical utility: uncertainty in Net Benefit; Laure Wynants
10:30-11:00		COFFEE BREAK						

Tuesday 29th August 2023

TIME		ROOM U6.6	ROOM U6.7	ROOM U6.8	ROOM U6.9	ROOM U6.10	ROOM U6.11	AULA MAGNA/GREAT HALL INVITED SESSIONS
		TO6 CLINICAL TRIALS 5	**TO7 SURVIVAL ANALYSIS 5**	**TO8 PREDICTION MODELS 2**	**TO9 LONGITUDINAL ANALYSIS 2**	**TO10 CLINICAL TRIALS 6**	**TO11 ItR-IBS & Italian Statistical Society**	**TIN2 - High-dimensional inference in biostatistics**
11:00 - 12:30	11:00	TO6.1 SAMPLE SIZE ESTIMATION FOR CLINICAL TRIALS USING COMPLEX RESPONDER ENDPOINTS; James Wason	TO7.1 FLEXIBLE PARAMETRIC ACCELERATED FAILURE TIME MODELS WITH CURE; Birzhan Akynkozhayev	TO8.1 COMPARING UNCERTAINTY IN INDIVIDUAL PROBABILITY PREDICTIONS WITH VARIOUS MODELS AND MODEL AVERAGE; Haoyue Wang	TO9.1 A WEIGHTED QUANTILE SUM REGRESSION WITH PENALIZED WEIGHTS AND TWO INDICES; Stefano Renzetti	TO10.1 MARGINAL ODDS RATIOS FOR CLUSTER RANDOMISED TRIALS: A NOVEL ANALYSIS METHOD; Jennifer Thompson	TO11.1 EXPLORING THE RELATIONSHIP WITH THE SELF-IMAGE IN THE DIGITAL ERA: INTEGRATING MODEL-BASED CLUSTERING AND GRAPHICAL MODEL APPROACHES; Chiara Brombin	**Organizer:** Francesco C. Stingo
	11:19	TO6.2 SAMPLE SIZE ADAPTATIONS IN CLINICAL TRIALS COMPARING RESTRICTED MEAN SURVIVAL TIMES – ADVANTAGES AND DRAWBACKS; Carolin Herrmann	TO7.2 PENALIZED LIKELIHOOD APPROACH FOR MIXTURE CURE MODEL WITH INTERVAL CENSORING - AN APPLICATION TO THIN MELANOMA; Serigne Lo	TO8.2 EVALUATING THE UNCERTAINTY OF THE RISK PREDICTED FROM THE TWO-STAGE LANDMARKING MODEL; Zhujie Gu	TO9.2 FLEXIBLE PARAMETRIC REGRESSION FOR CORRELATED DATA WITH TRANSFORMATION MODELS; Balint Tamasi	TO10.2 PSEUDO-VALUES REGRESSION FOR RESTRICTED MEAN SURVIVAL TIME IN SMALL SAMPLE CLUSTER RANDOMIZED TRIALS; Floriane Le Vilain--Abraham	TO11.2 THE AVERAGE UNEVEN MORTALITY INDEX: BUILDING ON THE "E-DAGGER" MEASURE OF LIFESPAN INEQUALITY; Marco Bonetti	TIN2.1 Spacex: gene co-expression network estimation for spatial transcriptomics; Veera Baladandayuthapani
	11:37	TO6.3 HYBRID SAMPLE SIZE CALCULATIONS FOR CLUSTER RANDOMISED TRIALS USING ASSURANCE; S. Faye Williamson	TO7.3 MIXTURE CURE SEMI-PARAMETRIC ACCELERATED FAILURE TIME MODELS WITH PARTLY INTERVAL-CENSORED DATA; Benoit Liquet	TO8.3 A SIMULATION APPROACH TO CALCULATING MINIMUM SAMPLE SIZES FOR PREDICTION MODELLING: THE PMSIMS PACKAGE FOR R; Ewan Carr	TO9.3 COMPARISON OF CONDITIONAL AND MARGINAL MEANS IN DISTRIBUTION BASED MARGINALIZED MULTILEVEL MODELS; Zsolt Lang	**TO10.3 - ONLINE** OPTIMAL STAIRCASE DESIGNS AND WHEN TO USE THEM; Kelsey Grantham	TO11.3 SIMULTANEOUS DIRECTIONAL INFERENCE; Aldo Solari	TIN2.2 Bayesian hierarchical models for large-scale pharmacogenomic screens of drug combinations; Manuela Zucknick
	11:55	TO6.4 A HYBRID APPROACH TO SAMPLE SIZE REESTIMATION IN CLUSTER RANDOMIZED TRIALS WITH CONTINUOUS OUTCOMES; Samuel Sarkodie	TO7.4 A FLEXIBLE BAYESIAN PREVALENCE-INCIDENCE MIXTURE MODEL FOR SCREENING DATA; Thomas Klausch	TO8.4 SYNTHESIS CALIBRATION CURVES; Johanna Munoz	TO9.4 USE OF PRIORS IN AUTOMATED MODEL BUILDING STRATEGIES FOR NON LINEAR MIXED EFFECTS MODELS; Melanie Prague	TO10.4 FINDING COST-EFFICIENT INCOMPLETE STEPPED WEDGE DESIGNS USING AN ITERATIVE APPROACH; Ehsan Rezaei	TO11.4 TREATMENT EFFECTASSESSMENT IN OBSERVATIONAL STUDIES: A PROPENSITY SCORE METHOD BASED ON BAYESIAN NETWORKS; Clelia Di Serio	
	12:13	TO6.5 THE ANYTIME-VALID LOGRANK TEST FOR FLEXIBLE COLLABORATIVE META-ANALYSIS AND PLATFORM TRIALS; Judith ter Schure		TO8.5 ACCOUNTING FOR MISSING VALUES IN THE CALIBRATION AND APPLICATION OF PREDICTION MODELS; Bart Mertens	TO9.5 VARIABLE SELECTION WITH 'TOO' MANY ZERO-INFLATED PREDICTORS: A NONNEGATIVE GARROTE APPROACH; Mariella Gregorich	TO10.5 JOINT MODELLING FOR PHASE III CLINICAL TRIAL PRIMARY ENDPOINT ESTIMATION: SIMULATION STUDY AND APPLICATION; Antoine Pitoy		TIN2.3 Outcome-guided multi-view bayesian clustering for integrative omic data analysis; Paul Kirk
12:30-13:30		LUNCH BREAK						

Wednesday 30th August 2023

TIME		ROOM U6.6	ROOM U6.7	ROOM U6.8	ROOM U6.9	ROOM U6.10	ROOM U6.11	AULA MAGNA/GREAT HALL INVITED SESSIONS
09:00-10:30		**WO1** CLINICAL TRIALS 7 AND AGM ISCB	**WO2** SURVIVAL ANALYSIS 6	**WO3** LONGITUDINAL ANALYSIS 3	**WO4** CAUSAL INFERENCE 3	**WO5** MISSING DATA	**WO6** EPIDEMIOLOGY 2	**WIN1** - Recurrent events and their use in medical studies
9:00 - 10:30	09:00	WO1.1 METHODS FOR ASSESSMENT OF FREQUENTIST OPERATING CHARACTERISTICS IN BAYESIAN TRIALS; Shirin Golchi	WO2.1 THE SHAPE OF THE RELATIVE FRAILTY VARIANCE INDUCED BY DISCRETE RANDOM EFFECTS IN TIME-TO-EVENT MODELS; Maximilian Bardo	WO3.1 HOW RESAMPLING METHODS CAN IMPROVE VARIABLE SELECTION IN LONGITUDINAL MODELS; Paola Rancoita	WO4.1 DATA-DRIVEN MODEL BUILDING FOR LIFE-COURSE EPIDEMIOLOGY; Claus Ekstrøm	WO5.1 SUBSTANTIVE MODEL COMPATIBLE MULTILEVEL MULTIPLE IMPUTATION: A JOINT MODELING APPROACH; James Carpenter	WO6.1 A CASE-CONTROL STUDY TO EVALUATE BLOOD BACTERIAL DNA IN THE INTESTINAL ADENOMA-CARCINOMA SEQUENCE; Marta Rossi	**Organizer:** Thomas Scheike
	09:19	WO1.2 OPTIMAL ADAPTIVE DESIGNS FOR TIME-TO-EVENT DATA: A SIMULATION STUDY; Nico Bruder	WO2.2 FAMILY HISTORY IN BREAST CANCER DEVELOPMENT; Maria Veronica Vinattieri	WO3.2 DYNAMIC PREDICTION OF AN EVENT USING MULTIPLE LONGITUDINAL MARKERS: A MODEL AVERAGING APPROACH; Taban Baghfalaki	**WO4.2 - ONLINE** OUTCOME- VERSUS EXPOSURE-WIDE FRAMEWORK IN MOLECULAR EPIDEMIOLOGY: FALSE POSITIVE FINDINGS DUE TO CORRELATION; Solène Cadiou	WO5.2 HANDLING MISSING DATA IN BINARY VARIABLES WITH LOW PREVALENCE; HAOXIANG GAO	WO6.2 INTEGRATING DATA ACROSS MULTIPLE SITES TO EXAMINE ASSOCIATIONS BETWEEN A METAL MIXTURE AND CHILD COGNITION; Elena Colicino	WIN1.1 Estimans for recurrent event endpoints; Mouna Akacha
	09:37	WO1.3 CONFIRMATORY ADAPTIVE ENRICHMENT DESIGNS WITH A NORMALLY DISTRIBUTED OUTCOME; Nigel Stallard	WO2.3 FLEXIBLE TIME-TO-EVENT MODELS FOR DOUBLE-INTERVAL-CENSORED DATA WITH A COMPETING EVENT; Jordache Ramjith	WO3.3 NON-PARAMETRIC CLUSTERING OF MULTIVARIATE LONGITUDINAL DATA: IDENTIFYING SUB-PHENOTYPES OF ALZHEIMER'S DISEASE; Anaïs Rouanet	WO4.3 RESAMPLING-BASED CONFIDENCE INTERVALS AND BANDS FOR THE AVERAGE TREATMENT EFFECT IN TIME-TO-EVENT DATA; Jasmin Rühl	WO5.3 ADVANCED BAYESIAN JOINT MODELLING FOR TIME-TO-EVENT SUBGROUP ANALYSIS WITH PARTIALLY MISSING SUBGROUP STATUS; Daniel Bratton	**WO6.3 - ONLINE** HIERARCHICAL CLUSTERING FOR THE EVALUATION OF TRANSITIVITY ASSUMPTION IN A NETWORK OF INTERVENTIONS; Loukia Spineli	WIN1.2 Estimating the marginal and conditional means of recurrent events in presence of terminal events; Giuliana Cortese
	09:55	WO1.4 ADAPTIVE ENRICHMENT CLINICAL TRIAL DESIGNS USING JOINT MODELLING OF LONGITUDINAL AND TIME-TO-EVENT DATA; Abigail Burdon	WO2.4 MODEL ASSESSMENT IN REGRESSION WITH A DOUBLY TRUNCATED RESPONSE; Jacobo de Uña-Álvarez	WO3.4 SHARED-PARAMETER MODELLING OF LONGITUDINAL DATA ALLOWING FOR POSSIBLY INFORMATIVE VISITING PROCESS AND DROPOUT ; Christos Thomadakis	WO4.4 SIMULATING COLLIDER STRATIFICATION BIAS AND AN APPLICATION TO THE INVERSE OBESITY PARADOX IN PROSTATE CANCER; Josef Fritz	WO5.4 IMPUTATION OF LONGITUDINAL PATIENT REPORTED OUTCOMES IN THE PRESENCE OF DEATH AND OTHER INTERCURRENT EVENTS; Doranne Thomassen	WO6.4 BAYESIAN UNANCHORED ADDITIVE MODELS FOR COMPONENT NETWORK META-ANALYSIS; Augustine Wigle	
	10:13	WO1.5 A TWO-STAGE BAYESIAN ADAPTIVE UMBRELLA DESIGN BORROWING INFORMATION OVER THE CONTROL DATA; Luke Ouma	WO2.5 MODELLING EXCESS MORTALITY COMPARING TO A CONTROL POPULATION: A COMBINED ADDITIVE AND RELATIVE HAZARDS MODEL; Caroline Weibull	WO3.5 IMPACT OF PARTIAL INFORMATION IN LONGITUDINAL GROUP-SEQUENTIAL DESIGNS ON PROBABILITY OF SUCCESS CALCULATIONS; Graham Wheeler	WO4.5 EVALUATE APPLICATION OF CAUSAL MACHINE LEARNING TO ADAPTIVE ENRICHMENT CLINICAL TRIALS; Jun Yin	WO5.5 THE MIDOC R PACKAGE: PROVIDING EXPERT GUIDANCE AND METHODOLOGY FOR MULTIPLE IMPUTATION; Elinor Curnow	WO6.5 GENERALIZED FUSED LASSO FOR TREATMENT POOLING IN NETWORK META-ANALYSIS; Audrey Beliveau	WIN1.3 Dealing with competing risks in the analysis of recurrent event; Per Kragh Andersen
10:30-11:00		**COFFEE BREAK**						
	11:00-12:30	**GREAT HALL** **PLE2: Plenary Lecture 2: President's Invited Speaker** **Vanessa Didelez** ***"On causal inference, estimands and trials in epidemiology and biostatistics"***						
12:30-13:30		**LUNCH BREAK and Annual General Meeting (AGM) ISCB at ROOM U6.6**						

Wednesday 30th August 2023

TIME		ROOM U6.6	ROOM U6.7	ROOM U6.8	ROOM U6.9	ROOM U6.10	ROOM U6.11	AULA MAGNA/GREAT HALL INVITED SESSIONS
		WO7 CLINICAL TRIALS 8	**WO8** SURVIVAL ANALYSIS 7	**WO9** PREDICTION MODELS 3	**WO10** CAUSAL INFERENCE 4	**WO11** MACHINE LEARNING 3	**WO12** SYNTETIC DATA 1	**WIN2** - Quantification of safety signals in clinical trials: Estimand, estimation, and how would good look like in ten years?
13:30 - 15:00	13:30	WO7.1 UTILIZING CO-PRIMARY ENDPOINTS TO TEST FOR CLINICALLY SIGNIFICANT DIFFERENCES IN PROGRESSION-FREE SURVIVAL; Michael LeBlanc	13:20 - Dedicated to Prof. Marubini WO8.1 COMPETING RISKS, THE FINE-GRAY MODEL, AND PSEUDOVALUES; Terry Therneau	WO9.1 CAUSAL BLIND SPOTS IN RISK-BASED DECISION MAKING; Nan van Geloven	WO10.1 FROM DATA TO DECISIONS: HOW EFFECTS OF INTERVENING VARIABLES CAN GUIDE POLICIES; Mats Stensrud	WO11.1 (CO-)CLUSTERING MODELS FOR SPATIAL TRANSCRIPTOMICS; Andrea Sottosanti	WO12.1 FROM CLINICAL TRIAL SIMULATIONS TO IN-SILICO TRIALS; Tim Friede	**Organizer:** Kaspar Rufibach
	13:49	WO7.2 ANALYSIS OF MULTICENTRE TRIALS: LIMITING THE EFFECT OF CENTRE HETEROGENEITY ON THE MARGINAL TREATMENT EFFECT; Mollie Payne	WO8.2 ANALYZING RESTRICTED MEAN SURVIVAL TIME CURVES USING PSEUDO-VALUES AND MACHINE LEARNING; Matteo Di Maso	WO9.2 RISK-BASED DECISION MAKING:FORMULATING ESTIMANDS FOR PREDICTION UNDER HYPOTHETICAL INTERVENTIONS; Kim Luijken	WO10.2 METHODOLOGY FOR SYSTEMATIC IDENTIFICATION AND ANALYSIS OF MULTIPLE BIASES IN CAUSAL INFERENCE; Rushani Wijesuriya	WO11.2 BAYESIAN RANK-BASED CLUSTERING VIA MALLOWS MIXTURES WITH COVARIATES FOR CANCER SUBTYPING; Emilie Eliseussen	WO12.2 THE CHALLENGES, FEASIBILITY AND LIMITS OF STATISTICAL ANALYSIS ON PURELY SYNTHETIC BIOMEDICAL DATA; Luca Carmisciano	WIN2.2 Estimands for safety – one size fits all?; Anja Loos
	14:07	WO7.3 DETERMINING THE MINIMUM DURATION OF TREATMENT IN TUBERCULOSIS: AN ORDER-RESTRICTED NON-INFERIORITY DESIGN; Alessandra Serra	WO8.3 A COMPARISON OF KAPLAN--MEIER-BASED INVERSE PROBABILITY OF CENSORING WEIGHTED REGRESSION METHODS; Morten Overgaard	WO9.3 IMPROVING LOCAL PREDICTION MODELS USING SIMILARITY BASED DATA POOLING; Max Behrens	WO10.3 INSTRUMENTAL VARIABLE ANALYSIS WITH CATEGORICAL TREATMENT AND ORDINAL INSTRUMENT; Amirhossein Kazemi	WO11.3 A CLUSTERING APPROACH TO MULTIPLE TIME-TO-EVENT DATA AND APPLICATION TO MULTIMORBIDITY ASSOCIATED WITH STROKE; Marc Delord	WO12.3 DATA-GENERATING MODELS OF LONGITUDINAL CONTINUOUS OUTCOMES AND INTERCURRENT EVENTS TO EVALUATE ESTIMANDS; Marian Mitroiu	WIN2.3 Adverse events with survival outcomes: from clinical questions to methods for statistical analysis; Laura Antolini
	14:25	WO7.4 ON THE DESIGN OF BIOMARKER-DRIVEN TRIALS WITH MEASUREMENT ERROR FOR TIME TO EVENT OUTCOMES; Susan Halabi	WO8.4 QUADRATIC INFERENCE FUNCTIONS AS A NEW APPROACH TO ANALYZE PSEUDO OBSERVATIONS IN SURVIVAL ANALYSIS; Léa Orsini	WO9.4 SIMILARITY QUANTIFICATION FOR SMALL DATA; Maryam Farhadizadeh	WO10.4 JUST WHA; T THE DOCTOR ORDERED: AN EVALUATION OF PROVIDER PREFERENCE-BASED INSTRUMENTAL VARIABLE METHODS; Laura Guedemann	WO11.4 IDENTIFICATION OF NOVEL DILATED CARDIOMYOPATHY SUB-PHENOTYPES: UNSUPERVISED CLUSTERING FOR MIXED-DATA TYPE ; Ilaria Gandin	WO12.4 A SIMPLE YET EFFECTIVE APPROACH FOR SYNTHETIC CLINICAL DATA GENERATION WITH REALISTIC MARGINAL DISTRIBUTIONS; Kiana Farhadyar	WIN2.1 Principled approach to time-to-event endpoints with competing risks, with a focus on analysis of aes; Kaspar Rufibach
	14:43	WO7.5 A SUPERLEARNER-ENFORCED APPROACH FOR THE ESTIMATION OF TREATMENT EFFECT IN PEDIATRIC TRIALS; Azzolina Danila	WO8.5 CLINICAL IMPACT AND DISEASE DYNAMICS IN COMPETING RISKS: AN ANALYSIS OF TWO HISTORICAL CLINICAL TRIALS; Giacomo Biganzoli	WO9.5 PREDICTING RESPONSE UNDER INTERVENTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A METHODOLOGICAL EXPLORATION; Celina Gehringer	WO10.5 PRACTICAL CONSIDERATIONS OF USING NEGATIVE CONTROL EXPOSURES TO DETECT RESIDUAL CONFOUNDING; Daniel Nevo		WO12.5 A SIMPLE-TO-USE R PACKAGE FOR MIMICKING STUDY DATA BY SIMULATIONS; Andreas Ziegler	WIN2.4 Regulatory perspective on the analysis of safety in clinical trials and beyond; Kit Roes
15:00-15:30		COFFEE BREAK						

Wednesday 30th August 2023

TIME		ROOM U6.6	ROOM U6.7	ROOM U6.8	ROOM U6.9	ROOM U6.10	ROOM U6.11	AULA MAGNA/GREAT HALL INVITED SESSIONS
		WO13 CLINICAL TRIALS 9	**WO14 MISCELLANEA**	**WO15 PRECISION MEDICINE 2**	**WO16 LONGITUDINAL ANALYSIS 4**	**WO17 HIGH DIMENSIONAL DATA 3**		**WIN 3 - Marginal versus conditional effects in clinical trials**
15:30 - 17:00	15:30	WO13.1 BASKET TRIAL DESIGNS BASED ON POWER PRIORS THAT INCORPORATE OVERALL HETEROGENEITY; Lukas Baumann	WO14.1 IMPROVE CLINICAL AND METHODOLOGICAL RESEARCH BY ADHERENCE TO REPORTING GUIDELINES AND STRUCTURED REPORTING; Willi Sauerbrei	WO15.1 OPTIMIZING INFORMATION BORROWING FOR BAYESIAN HIERARCHICAL MODEL IN SUBGROUP ANALYSIS; J. Jack Lee	WO16.1 EXTENDED JOINT MODELS UNDER THE BAYESIAN APPROACH USING JMBAYES2; Dimitris Rizopoulos	WO17.1 CO-CLUSTERING MATRIX TRI-FACTORIZATION: SPATIAL AND FEATURES CONSTRAINTS; Giulia Capitoli		**Organizer:** Jonathan Bartlett WIN3.1 A value system for evaluating estimands in randomized trials; David Benkeser WIN3.2 Conditional vs. marginal effects in randomized trials: tradeoffs; Michael Rosenblum WIN3.3 Why do we worry about marginal inference?; Stephen Senn WIN3.4 Covariate adjustment and exploiting ordinality: simulations of power and a rieview of neurological trials; Ewout Steyerberg
	15:49	WO13.2 APPLICATION OF CONSTRAINED OPTIMIZATION TECHNIQUES TO BAYESIAN BASKET TRIAL DESIGNS; Lukas D. Sauer	WO14.2 CONFIDENCE INTERVALS USING APPROXIMATE PROPAGATION OF IMPRECISION; John Ferguson	WO15.2 PRIORITISING THE OUTCOME IN BAYESIAN PROFILE REGRESSION: AN APPLICATION TO OSTEOARTHRITIS PROTEOMIC DATA; Laura Bondi	WO16.2 BAYESIAN INFERENCE FOR JOINT MODELS OF LONGITUDINAL AND SURVIVAL DATA WITH DYNAMIC RISK PREDICTION; Denis Rustand	WO17.2 PROCRUSTES ANALYSIS FOR SPATIAL TRANSCRIPTOMICS DATA; Daniela Corbetta		
	16:07	WO13.3 FREQUENTIST ANALYSIS OF BASKET TRIALS WITH ONE-SAMPLE MANTEL-HAENSZEL PROCEDURES; Satoshi Hattori	WO14.3 NONPARAMETRIC BAYESIAN ANALYSIS OF SURVIVAL DATA WITH SPATIALLY CORRELATED CLUSTER EFFECTS USING SOFT-BART; DEBAJYOTI SINHA	WO15.3 BAYESIAN SEQUENTIAL DESIGN FOR IDENTIFIYING AND RANKING OF SUBGROUPS BASED ON BIOMARKERS IN SEPSIS'S PATIENTS; Valentin Vinnat	WO16.3 JOINT ANALYSIS OF DISEASE PROGRESSION MARKERS AND DEATH USING INDIVIDUAL TEMPORAL RECALIBRATION; Tiphaine Saulnier	WO17.3 STATISTICAL INTEGRATION OF MULTI-OMICS AND DRUG SCREENING DATA FROM CELL LINES; Said El Bouhaddani		
	16:25	WO13.4 NON-CONCURRENT CONTROLS IN PLATFORM TRIALS: SEPARATING RANDOMISED AND NON-RANDOMISED INFORMATION; Ian Marschner	WO14.4 SURVEY SAMPLING METHODS FOR PARTIAL VERIFICATION BIAS IN DIAGNOSTIC EVALUATION STUDIES; Katherine Thomas	WO15.5 STATISTICAL INFERENCE FOR ROC CURVES AFTER THE BOX-COX TRANSFORMATION AND USE OF THE R PACKAGE `ROCBC'; Christos Nakas	WO16.4 A LAMBERT FUNCTION-BASED PROCEDURE TO FIT JOINT MODELS FOR MULTIVARIATE LONGITUDINAL AND TIME-TO-EVENT DATA; Hadrien Charvat	WO17.4 ANALYSIS OF COMPOSITIONAL MICROBIOME DATA WITH BIAS CORRECTION USING POISSON FRAMEWORK; Connie Musisi		
	16:43		WO14.5 OPTIMAL TWO-STAGE SAMPLING FOR MEAN ESTIMATION IN MULTILEVEL POPULATIONS WHEN CLUSTER SIZE IS INFORMATIVE; Francesco Innocenti	WO15.6 TREATMENT EFFECT ESTIMATION FOR TIME-TO-EVENT OUTCOMES IN OVERLAPPING SUBGROUPS BASED ON SHRINKAGE METHODS ; Marcel Wolbers	WO16.5 A NOVEL PLATFORM FOR ANALYZING SEMI-CONTINUOUS MEDICAL COST AND SURVIVAL DATA; Mohadeseh Shojaei Shahrokhabadi	WO17.5 QUANTIFYING UNCERTAINTY IN DEEP GENERATIVE SYNTHESIS OF TABULAR MEDICAL DATA WITH BAYESIAN INFERENCE; Patric Tippmann		